Menu
Recruiting NCT06902714

Effects of Oral Tranexamic Acid on Short Term Postoperative Outcomes Following Total Shoulder Arthroplasty

Phase III Interventional Shoulder Arthroplasty

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: oral tranexamic acid, Placebo.
Who it may be relevant to
Registry conditions: Shoulder Arthroplasty. Basic parameters: 18 years — 79 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Evaluating the Effects of Oral Tranexamic Acid on Short Term Postoperative Outcomes Following Total Shoulder Arthroplasty: A Randomized Control Trial

Overview

The purpose of this clinical trial is to evaluate the short-term clinical outcomes of patients undergoing total shoulder arthroplasty who receive an extended postoperative course of oral tranexamic acid

Interventions

  • Drug oral tranexamic acid
    one group of subjects will receive oral tranexamic acid and the other will receive oral placebo
  • Drug Placebo
    one group of randomized subjects will receive placebo and the other will receive oral tranexamic acid

Primary outcome measures

  • VAS [Time frame: 2 weeks]

Eligibility criteria

Inclusion criteria

  • Skeletally mature patients (ages 18-79) undergoing primary total shoulder arthroplasty

Exclusion criteria

  • Patients with Cancer, venous thromboembolism, stroke, heart disease, pregnant or nursing, allergic to TXA, current tobacco use, anticoagulants other than aspirin.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Triple blind
Primary purpose
Treatment

Study locations

United States · 1 center
  • University of Alabama at Birmingham — Birmingham

Identifiers

NCT: NCT06902714 · IRB-300014204 · UAB

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗